221 related articles for article (PubMed ID: 36232517)
1. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
[TBL] [Abstract][Full Text] [Related]
2. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
3. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
4. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
[TBL] [Abstract][Full Text] [Related]
5. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
6. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
Belk KW; Laposata M; Craver C
J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
[TBL] [Abstract][Full Text] [Related]
7. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
[TBL] [Abstract][Full Text] [Related]
8. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
[TBL] [Abstract][Full Text] [Related]
9. An Overview of Heparin Monitoring with the Anti-Xa Assay.
Dean CL
Methods Mol Biol; 2023; 2663():343-353. PubMed ID: 37204722
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
[TBL] [Abstract][Full Text] [Related]
12. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
13. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
14. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
[TBL] [Abstract][Full Text] [Related]
16. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
17. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
[TBL] [Abstract][Full Text] [Related]
18. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.
Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM
J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425
[TBL] [Abstract][Full Text] [Related]
19. Monitoring heparin anticoagulation in the acute phase response.
Uprichard J; Manning RA; Laffan MA
Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
[TBL] [Abstract][Full Text] [Related]
20. Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes.
Toulon P; Appert-Flory A; Fischer F; Buvat S; Jambou D; Mahagne MH
Thromb Res; 2020 Feb; 186():7-12. PubMed ID: 31837560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
